KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Halozyme Therapeutics (HALO) over the last 13 years, with Q4 2025 value amounting to $9.0 million.

  • Halozyme Therapeutics' Short-term Investments fell 9812.59% to $9.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $9.0 million, marking a year-over-year decrease of 9812.59%. This contributed to the annual value of $9.0 million for FY2025, which is 9812.59% down from last year.
  • Halozyme Therapeutics' Short-term Investments amounted to $9.0 million in Q4 2025, which was down 9812.59% from $282.3 million recorded in Q3 2025.
  • In the past 5 years, Halozyme Therapeutics' Short-term Investments registered a high of $668.3 million during Q1 2022, and its lowest value of $9.0 million during Q4 2025.
  • Its 5-year average for Short-term Investments is $313.4 million, with a median of $290.6 million in 2024.
  • As far as peak fluctuations go, Halozyme Therapeutics' Short-term Investments soared by 18242.16% in 2021, and later plummeted by 9812.59% in 2025.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Short-term Investments stood at $622.2 million in 2021, then tumbled by 79.33% to $128.6 million in 2022, then surged by 69.23% to $217.6 million in 2023, then surged by 120.66% to $480.2 million in 2024, then tumbled by 98.13% to $9.0 million in 2025.
  • Its Short-term Investments stands at $9.0 million for Q4 2025, versus $282.3 million for Q3 2025 and $486.3 million for Q2 2025.